• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

cardio

  1. CardioRenal NE Ohio Manager

    It seems there is a manager in NE Ohio who has been causing some trouble. As a rep in the area, I have heard from several of my offices that this individual has been banned from their offices due to his unprofessional behavior. To make matters worse, I have heard that he is attempting to recruit...
    • anonymous
    • Thread
    • bayer cardio
    • Replies: 33
    • Forum: Bayer

  2. Cardio Retail Sales rep commissions?

    Applying for a Cardio Retail Sales Rep position. Can anyone in this group advise if this role pays commission or other sales incentive? Is it a good role?
    • anonymous
    • Thread
    • cardio
    • Replies: 0
    • Forum: Janssen

  3. Boston Scientific 4Q Results

    Boston Scientific (BSX) reported a net loss of $615 million in the fourth quarter due to one-time income tax charge of $842 million. Adjusted earnings came in at $0.34 per share, which improved 13% vs. last year. MedSurg business grew 14% in the fourth quarter raking in $931 million. Check out...
Top Bottom
Back